ArticleCirculation reports2026
Prognostic Utility of Regional Longitudinal Strain in Patients With Immunoglobulin Light-Chain Cardiac Amyloidosis: A Report From the J-CASE Multicenter Survey.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiac amyloidosis: what every interventional cardiologist should know.Cardiovascular intervention and therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the prognostic impact of left ventricular (LV) regional longitudinal strain (LS) in patients with immunoglobulin light-chain (AL) cardiac amyloidosis. Methods and Results: The study population was part of the Japan Cardiac Amyloidosis Survey of typical Echocardiographic findings (J-CASE) study - a multicenter, retrospective study with 18 participating institutions in Japan. From a total of 324 patients with histologically proven cardiac amyloidosis enrolled between 2000 and 2020, we enrolled 81 patients with AL cardiac amyloidosis in the present study. During a median follow up of 278 days (interquartile range 63-1,133 days), 43 all-cause deaths occurred. LV-apical LS was significantly and independently associated with all-cause death after adjusting for conventional echocardiographic findings (hazard ratio 0.86; 95% confidence interval; P<0.05). Receiver operating characteristic curve analysis showed that the area under the curve for LV-apical LS for all-cause death was 68% and the best cut-off value for LV-apical LS was 15.9% (sensitivity 71%; specificity 54%). Kaplan-Meier analysis demonstrated a significantly higher risk of all-cause death in patients with low LV-apical LS (<15.9%, n=46) than in those with high LV-apical LS (≥15.9%, n=35; log-rank test P<0.05). Conclusions: Low LV-apical LS is a significant and independent prognostic factor in patients with AL cardiac amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.